| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 22/08/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 11/08/2023 | 22:20 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 09/08/2023 | 14:30 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 01/08/2023 | 21:37 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 21/07/2023 | 22:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/07/2023 | 22:25 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 20/07/2023 | 22:05 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 18/07/2023 | 14:00 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 17/07/2023 | 14:30 | GlobeNewswire Inc. | Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 07/07/2023 | 20:52 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 26/06/2023 | 12:16 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 23/06/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 07/06/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 02/06/2023 | 18:30 | GlobeNewswire Inc. | LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023 | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 30/05/2023 | 14:30 | GlobeNewswire Inc. | Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology’s Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 10/05/2023 | 14:31 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 24/04/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 04/04/2023 | 14:30 | GlobeNewswire Inc. | LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 29/03/2023 | 14:32 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 14/02/2023 | 19:50 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 07/02/2023 | 18:16 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 05/01/2023 | 17:01 | Edgar (US Regulatory) | Amended Statement of Changes in Beneficial Ownership (4/a) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 04/01/2023 | 17:09 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 19/12/2022 | 12:03 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 13/10/2022 | 14:30 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 26/08/2022 | 20:51 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 26/08/2022 | 20:50 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 16/08/2022 | 12:06 | Edgar (US Regulatory) | Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 28/07/2022 | 22:19 | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |
| 21/06/2022 | 14:30 | GlobeNewswire Inc. | LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS | NASDAQ:LIXT | Lixte Biotechnology Holdings Inc |